Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ongoing FDA Modernization Is Focus Of AdvaMed 2001 Legislative Spotlight

This article was originally published in The Gray Sheet

Executive Summary

A congressional hearing tentatively scheduled to take place by mid-2001 will examine the ability of FDA to approve breakthrough medical technology in a timely fashion, according to the medical device trade group AdvaMed.

You may also be interested in...



Oversight Chairman Greenwood Familiar With Third-Party Review Program

Any legislative proposal to expand FDA's third-party review program to applications containing clinical data would have a powerful ally in Rep. Jim Greenwood (R-Penn.), the newly named chair of the House Energy and Commerce/Oversight Subcommittee.

Oversight Chairman Greenwood Familiar With Third-Party Review Program

Any legislative proposal to expand FDA's third-party review program to applications containing clinical data would have a powerful ally in Rep. Jim Greenwood (R-Penn.), the newly named chair of the House Energy and Commerce/Oversight Subcommittee.

Device Lobbyist Kimbell Serving On Bush HHS Transition Advisory Team

Jeff Kimbell is the device industry's point-person on the incoming administration's Health and Human Services transition advisory team.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel